CAS 1254036-77-5

GSK-2269557

Description:

GSK-2269557 is a chemical compound that belongs to a class of molecules known as small-molecule inhibitors. It was developed by GlaxoSmithKline and is primarily investigated for its potential therapeutic applications in the treatment of various diseases, particularly in the field of oncology. The compound acts as a selective inhibitor of certain kinases, which are enzymes that play crucial roles in cell signaling pathways, including those involved in cell growth and proliferation. This inhibition can lead to the modulation of tumor growth and survival, making it a candidate for cancer treatment. GSK-2269557 is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity and pharmacokinetic properties. As with many investigational drugs, its safety, efficacy, and mechanism of action are subjects of ongoing research and clinical trials. Understanding its characteristics, including solubility, stability, and interaction with biological targets, is essential for its development as a therapeutic agent.

Formula: C₂₆H₂₉ClN₆O

Synonyms:

• GSK-2269557
• GSK-2269557 (Nemiralisib HCl)
• 6-(1H-Indol-4-yl)-4-[5-[[4-(1-methylethyl)-1-piperazinyl]methyl]-2-oxazolyl]-1H-indazole hydrochloride (1:1)
• 2-(6-(1H-Indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole hydrochloride
• CS-2463
• GSK-2269557 HCl salt
• GSK2269557 HCL
• 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hydrochloride

2-(6-(1H-Indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole hydrochloride

CAS: 1254036-77-5

Formula: C₂₆H₂₈N₆O

Molecular weight: 440.5401

Ref: IN-DA000NMS

Nemiralisib HCl

CAS: 1254036-77-5

Nemiralisib HCl is a small molecule that inhibits the activity of two proteins, PD-L1 and p-glycoprotein (Pgp), which are involved in the immune system. Nemiralisib HCl has been shown to be effective against cancer cells and inflammatory diseases. It also has pharmacokinetic properties that make it suitable for oral administration. Nemiralisib HCl binds to and inhibits lipid kinase, which is involved in the inflammatory response. Nemiralisib HCl has terminal half-life of approximately 23 hours, with an oral bioavailability of approximately 50%.

Formula: C₂₆H₂₉ClN₆O

Purity: Min. 95%

Molecular weight: 477.01 g/mol

Ref: 3D-EAC03677